Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report

Yuji Kitaichi,1 Takeshi Inoue,1 Nobuyuki Mitsui,1 Shin Nakagawa,1 Rie Kameyama,1 Yoshiyuki Hayashishita,1 Tohru Shiga,2 Ichiro Kusumi,1 Tsukasa Koyama1 1Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan; 2Department of Nuclear Medicine, Graduate School of Med...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kitaichi Y, Inoue T, Mitsui N, Nakagawa S, Kameyama R, Hayashishita Y, Shiga T, Kusumi I, Koyama T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/fd61bbf02b9a4995b8c48db7ac1b955d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fd61bbf02b9a4995b8c48db7ac1b955d
record_format	dspace
spelling	oai:doaj.org-article:fd61bbf02b9a4995b8c48db7ac1b955d2021-12-02T06:19:00ZSelegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report1176-63281178-2021https://doaj.org/article/fd61bbf02b9a4995b8c48db7ac1b955d2013-10-01T00:00:00Zhttp://www.dovepress.com/selegiline-remarkably-improved-stage-5-treatment-resistant-major-depre-a14709https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Yuji Kitaichi,1 Takeshi Inoue,1 Nobuyuki Mitsui,1 Shin Nakagawa,1 Rie Kameyama,1 Yoshiyuki Hayashishita,1 Tohru Shiga,2 Ichiro Kusumi,1 Tsukasa Koyama1 1Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan; 2Department of Nuclear Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan Abstract: We report a case in which selegiline, an irreversible monoamine oxidase B (MAO-B) inhibitor, greatly improved depressive symptoms in an adult with stage 5 treatment-resistant major depressive disorder. Four antidepressants and four augmentation therapies had previously been ineffective or intolerable, and electroconvulsive therapy had only a temporary effect. After 20 weeks of treatment with selegiline (10 mg/day), the patient's score on the 17-item Hamilton Depression Rating Scale (HDRS) had decreased from 19 to 4 points. [18F]-Fluorodeoxyglucose positron emission tomography (FDG-PET) showed increased glucose metabolism in the bilateral basal ganglia after initiating selegiline treatment; blood dopamine levels were also increased after selegiline treatment. These results raise the possibility that selegiline enhances dopaminergic neural transmission in treatment-resistant depression, thus leading to an improvement in depressive symptoms. Keywords: treatment-resistant depression, FDG-PET, glucose metabolism, basal gangliaKitaichi YInoue TMitsui NNakagawa SKameyama RHayashishita YShiga TKusumi IKoyama TDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 1591-1594 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Kitaichi Y Inoue T Mitsui N Nakagawa S Kameyama R Hayashishita Y Shiga T Kusumi I Koyama T Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
description	Yuji Kitaichi,1 Takeshi Inoue,1 Nobuyuki Mitsui,1 Shin Nakagawa,1 Rie Kameyama,1 Yoshiyuki Hayashishita,1 Tohru Shiga,2 Ichiro Kusumi,1 Tsukasa Koyama1 1Department of Psychiatry, Graduate School of Medicine, Hokkaido University, Sapporo, Japan; 2Department of Nuclear Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan Abstract: We report a case in which selegiline, an irreversible monoamine oxidase B (MAO-B) inhibitor, greatly improved depressive symptoms in an adult with stage 5 treatment-resistant major depressive disorder. Four antidepressants and four augmentation therapies had previously been ineffective or intolerable, and electroconvulsive therapy had only a temporary effect. After 20 weeks of treatment with selegiline (10 mg/day), the patient's score on the 17-item Hamilton Depression Rating Scale (HDRS) had decreased from 19 to 4 points. [18F]-Fluorodeoxyglucose positron emission tomography (FDG-PET) showed increased glucose metabolism in the bilateral basal ganglia after initiating selegiline treatment; blood dopamine levels were also increased after selegiline treatment. These results raise the possibility that selegiline enhances dopaminergic neural transmission in treatment-resistant depression, thus leading to an improvement in depressive symptoms. Keywords: treatment-resistant depression, FDG-PET, glucose metabolism, basal ganglia
format	article
author	Kitaichi Y Inoue T Mitsui N Nakagawa S Kameyama R Hayashishita Y Shiga T Kusumi I Koyama T
author_facet	Kitaichi Y Inoue T Mitsui N Nakagawa S Kameyama R Hayashishita Y Shiga T Kusumi I Koyama T
author_sort	Kitaichi Y
title	Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
title_short	Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
title_full	Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
title_fullStr	Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
title_full_unstemmed	Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
title_sort	selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/fd61bbf02b9a4995b8c48db7ac1b955d
work_keys_str_mv	AT kitaichiy selegilineremarkablyimprovedstage5treatmentresistantmajordepressivedisorderacasereport AT inouet selegilineremarkablyimprovedstage5treatmentresistantmajordepressivedisorderacasereport AT mitsuin selegilineremarkablyimprovedstage5treatmentresistantmajordepressivedisorderacasereport AT nakagawas selegilineremarkablyimprovedstage5treatmentresistantmajordepressivedisorderacasereport AT kameyamar selegilineremarkablyimprovedstage5treatmentresistantmajordepressivedisorderacasereport AT hayashishitay selegilineremarkablyimprovedstage5treatmentresistantmajordepressivedisorderacasereport AT shigat selegilineremarkablyimprovedstage5treatmentresistantmajordepressivedisorderacasereport AT kusumii selegilineremarkablyimprovedstage5treatmentresistantmajordepressivedisorderacasereport AT koyamat selegilineremarkablyimprovedstage5treatmentresistantmajordepressivedisorderacasereport
_version_	1718400031700025344

Selegiline remarkably improved stage 5 treatment-resistant major depressive disorder: a case report

Ejemplares similares